Advancing pipeline of research for people without modulators

A primary objective is to collect data on key clinical outcome endpoints, including changes in percent predicted forced expiratory volume in one second (ppFEV1) that are often used as endpoints in therapeutic trials to establish a repository of control data (e.g., in the absence of investigational drug use) in pwCF who are ineligible and/or not taking CFTR modulators. These data may be used in research or investigative efforts (e.g., for comparison with people exposed to experimental or new therapies in CF).